APA (7th ed.) Citation

C, R., C, S., D, D., R, F., CB, W., & V, H. (2022). Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) - A case series. European journal of cancer (Oxford, England : 1990), 174, 37. https://doi.org/10.1016/j.ejca.2022.07.013

Chicago Style (17th ed.) Citation

C, Rausch, Schwicht C, Doedens D, Forstpointner R, Westphalen CB, and Heinemann V. "Panitumumab Can Safely and Effectively Be Substituted for Cetuximab in the Treatment of BRAF V600Emut Metastatic Colorectal Cancer (mCRC) - A Case Series." European Journal of Cancer (Oxford, England : 1990) 174 (2022): 37. https://doi.org/10.1016/j.ejca.2022.07.013.

MLA (9th ed.) Citation

C, Rausch, et al. "Panitumumab Can Safely and Effectively Be Substituted for Cetuximab in the Treatment of BRAF V600Emut Metastatic Colorectal Cancer (mCRC) - A Case Series." European Journal of Cancer (Oxford, England : 1990), vol. 174, 2022, p. 37, https://doi.org/10.1016/j.ejca.2022.07.013.